Renée Aguiar-Lucander

Renée Aguiar-Lucander

Directeur Général chez HANSA BIOPHARMA AB

Fortune : 989 439 $ au 31/10/2026

64 ans
Health Technology
Commercial Services
Finance

Profil

Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA since 2025, AC Immune SA as Independent Director since 2025, Egalet A, and Ral Capital Ltd. (United Kingdom).
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously Chairman at EnXray Ltd. and Director at SpineVision SAS, ImpactRx, Inc., Zyla Life Sciences LLC (Independent Director), Pulmagen Therapeutics (Synergy) Ltd. (Non-Executive Director), MedCap AB (Independent Director), Newron Pharmaceuticals SpA (Independent Non-Executive Director, 2006–2011), SciBase Holding AB (Independent Director), NsGene A, Egalet Ltd. (Independent Director, 2013), Onyvax Ltd., Lehman Brothers, Inc. (Milan Branch) as Managing Director-Corporate Finance in 2003, Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, 3i Group Plc (Partner), 3i Venture Capital (Partner), and Omega Fund Management UK LLP as Chief Operating Officer & Partner.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
25/09/2026 197 000 ( 0,19 % ) 788 236 $ 31/10/2026
11/06/2026 51 136 ( 0,05 % ) 113 522 $ 31/10/2026
01/03/2026 24 700 ( 0,01 % ) 87 681 $ 31/10/2026

Postes actifs de Renée Aguiar-Lucander

SociétésPosteDébut
HANSA BIOPHARMA AB Directeur Général 24/04/2025
INVENTIVA Directeur/Membre du Conseil 22/05/2025
AC IMMUNE SA Directeur/Membre du Conseil 19/06/2025
Président -
Président -
Directeur/Membre du Conseil -
Ral Capital Ltd. (United Kingdom)
Directeur/Membre du Conseil -

Anciens postes connus de Renée Aguiar-Lucander

SociétésPosteFin
CALLIDITAS THERAPEUTICS AB Directeur Général 01/01/2025
ZYLA LIFE SCIENCES Directeur/Membre du Conseil 10/06/2015
░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Renée Aguiar-Lucander

Formation de Renée Aguiar-Lucander

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

65

Relations au 1er degré

29

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées29

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Omega Fund Management UK LLP

Finance

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Ral Capital Ltd. (United Kingdom)

  1. Bourse
  2. Insiders
  3. Renée Aguiar-Lucander
🔇